Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)

  • Technology appraisal
  • TA1006
  • Published: 
Download guidance (PDF)

Advice

NICE is unable to make a recommendation about the use in the NHS of empagliflozin for treating type 2 diabetes in people aged 10 to 17 years. This is because Boehringer Ingelheim has confirmed that it does not intend to make an evidence submission for the appraisal. Boehringer Ingelheim's view, which it has corroborated in consultation with healthcare professionals and other relevant decision makers, is that an appraisal will not add value.

Information

If NHS organisations wish to consider empagliflozin for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-6120-7